[1]
R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
[2]
R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
[3]
International Textbook of Diabetes Mellitus, 4th ed. John Wiley & Sons, Incorporated, 2015 [Online]. Available: http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437
[4]
‘Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/ng17
[5]
‘Type 2 diabetes in adults: management | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/ng28
[6]
S. Chatterjee, K. Khunti, and M. J. Davies, ‘Type 2 diabetes’, The Lancet, Feb. 2017, doi: 10.1016/S0140-6736(17)30058-2.
[7]
M. A. Atkinson, G. S. Eisenbarth, and A. W. Michels, ‘Type 1 diabetes’, The Lancet, vol. 383, no. 9911, pp. 69–82, Jan. 2014, doi: 10.1016/S0140-6736(13)60591-7.
[8]
A. S. de M. Matheus, L. R. M. Tannus, R. A. Cobas, C. C. S. Palma, C. A. Negrato, and M. de B. Gomes, ‘Impact of Diabetes on Cardiovascular Disease: An Update’, International Journal of Hypertension, vol. 2013, pp. 1–15, 2013, doi: 10.1155/2013/653789.
[9]
‘Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey’ [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335
[10]
‘Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947
[11]
R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, ‘10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes’, New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, Oct. 2008, doi: 10.1056/NEJMoa0806470.
[12]
‘Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)’, The Lancet, vol. 352, no. 9131, pp. 854–865, Sep. 1998, doi: 10.1016/S0140-6736(98)07037-8.
[13]
‘Effects of Intensive Glucose Lowering in Type 2 Diabetes’, New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, Jun. 2008, doi: 10.1056/NEJMoa0802743.
[14]
F. M. Turnbull et al., ‘Intensive glucose control and macrovascular outcomes in type 2 diabetes’, Diabetologia, vol. 52, no. 11, pp. 2288–2298, Nov. 2009, doi: 10.1007/s00125-009-1470-0.
[15]
‘Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes’, New England Journal of Medicine, vol. 364, no. 9, pp. 818–828, Mar. 2011, doi: 10.1056/NEJMoa1006524.
[16]
M. E. Miller et al., ‘The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study’, BMJ, vol. 340, no. jan08 1, pp. b5444–b5444, Jan. 2010, doi: 10.1136/bmj.b5444.
[17]
W. Duckworth et al., ‘Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes’, New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, Jan. 2009, doi: 10.1056/NEJMoa0808431.
[18]
R. A. Hayward et al., ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 372, no. 23, pp. 2197–2206, Jun. 2015, doi: 10.1056/NEJMoa1414266.
[19]
‘Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, Jun. 2008, doi: 10.1056/NEJMoa0802987.
[20]
M. G. Wong et al., ‘Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’, Diabetes Care, vol. 39, no. 5, pp. 694–700, May 2016, doi: 10.2337/dc15-2322.
[21]
F. Giorgino, P. D. Home, and J. Tuomilehto, ‘Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?’, Diabetes Care, vol. 39, no. Supplement 2, pp. S187–S195, Aug. 2016, doi: 10.2337/dcS15-3023.
[22]
P. Gæde, H. Lund-Andersen, H.-H. Parving, and O. Pedersen, ‘Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes’, New England Journal of Medicine, vol. 358, no. 6, pp. 580–591, Feb. 2008, doi: 10.1056/NEJMoa0706245.
[23]
‘The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus’, New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, Sep. 1993, doi: 10.1056/NEJM199309303291401.
[24]
‘Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes’, New England Journal of Medicine, vol. 353, no. 25, pp. 2643–2653, Dec. 2005, doi: 10.1056/NEJMoa052187.
[25]
T. J. Orchard et al., ‘Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality’, JAMA, vol. 313, no. 1, Jan. 2015, doi: 10.1001/jama.2014.16107.
[26]
P. Gæde et al., ‘Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial’, Diabetologia, vol. 59, no. 11, pp. 2298–2307, Nov. 2016, doi: 10.1007/s00125-016-4065-6.
[27]
C. Bianchi, R. Miccoli, and S. Del Prato, ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’, Current Diabetes Reports, vol. 13, no. 3, pp. 403–410, Jun. 2013, doi: 10.1007/s11892-013-0371-2.
[28]
B. Zinman et al., ‘Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes’, New England Journal of Medicine, vol. 373, no. 22, pp. 2117–2128, Nov. 2015, doi: 10.1056/NEJMoa1504720.
[29]
S. P. Marso et al., ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.
[30]
R. Boussageon et al., ‘Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials’, BMJ, vol. 343, no. jul26 1, pp. d4169–d4169, Jul. 2011, doi: 10.1136/bmj.d4169.
[31]
K. K. Ray et al., ‘Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials’, The Lancet, vol. 373, no. 9677, pp. 1765–1772, May 2009, doi: 10.1016/S0140-6736(09)60697-8.
[32]
A. Sultan et al., ‘Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study’, Diabetic Medicine, Apr. 2017, doi: 10.1111/dme.13364.
[33]
A. Rawshani et al., ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’, New England Journal of Medicine, vol. 376, no. 15, pp. 1407–1418, Apr. 2017, doi: 10.1056/NEJMoa1608664.
[34]
A. Sultan et al., ‘Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study’, Diabetic Medicine, Apr. 2017, doi: 10.1111/dme.13364.
[35]
E. Z. Soliman, J.-Y. C. Backlund, I. Bebu, T. J. Orchard, B. Zinman, and J. M. Lachin, ‘Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study’, Diabetes Care, vol. 40, no. 6, pp. 793–799, Jun. 2017, doi: 10.2337/dc16-2050.
[36]
S. D. Solomon et al., ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’, Diabetes Care, vol. 40, no. 6, p. 809.3-809, Jun. 2017, doi: 10.2337/dc17-er06e.
[37]
E. J. Mayer-Davis et al., ‘Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012’, New England Journal of Medicine, vol. 376, no. 15, pp. 1419–1429, Apr. 2017, doi: 10.1056/NEJMoa1610187.
[38]
A. Rawshani et al., ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’, New England Journal of Medicine, vol. 376, no. 15, pp. 1407–1418, Apr. 2017, doi: 10.1056/NEJMoa1608664.
[39]
‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’, New England Journal of Medicine, vol. 377, no. 3, pp. 300–301, Jul. 2017, doi: 10.1056/NEJMc1706292.
[40]
‘Older antidiabetic drugs | The British Journal of Cardiology’. [Online]. Available: https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/
[41]
‘Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
[42]
R. R. Holman et al., ‘Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 377, no. 13, pp. 1228–1239, Sep. 2017, doi: 10.1056/NEJMoa1612917.
[43]
R. J. Pickering, C. J. Rosado, A. Sharma, S. Buksh, M. Tate, and J. B. de Haan, ‘Recent novel approaches to limit oxidative stress and inflammation in diabetic complications’, Clinical & Translational Immunology, vol. 7, no. 4, 2018, doi: 10.1002/cti2.1016.
[44]
‘Microvascular Complications and Foot Care’, Diabetes Care, vol. 40, no. Supplement 1, pp. S88–S98, Jan. 2017, doi: 10.2337/dc17-S013.
[45]
W. M. Valencia and H. Florez, ‘How to prevent the microvascular complications of type 2 diabetes beyond glucose control’, BMJ, Jan. 2017, doi: 10.1136/bmj.i6505.
[46]
‘Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies’, The Lancet, vol. 375, no. 9733, pp. 2215–2222, Jun. 2010, doi: 10.1016/S0140-6736(10)60484-9.
[47]
‘The changing face of diabetes complications - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109
[48]
M. G. Wong et al., ‘Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’, Diabetes Care, vol. 39, no. 5, pp. 694–700, May 2016, doi: 10.2337/dc15-2322.
[49]
‘Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death’, New England Journal of Medicine, vol. 364, no. 9, pp. 829–841, Mar. 2011, doi: 10.1056/NEJMoa1008862.
[50]
S. G. Wannamethee, A. G. Shaper, P. H. Whincup, L. Lennon, and N. Sattar, ‘Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel rosk factors’, Archives of Internal Medicine, vol. 171, no. 5, Mar. 2011, doi: 10.1001/archinternmed.2011.2.
[51]
J. S. Yudkin, B. Richter, and E. A. Gale, ‘Intensified glucose control in type 2 diabetes—whose agenda?’, The Lancet, vol. 377, no. 9773, pp. 1220–1222, Apr. 2011, doi: 10.1016/S0140-6736(10)61112-9.
[52]
C.-Y. Zhang et al., ‘Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis’, Annals of Medicine, vol. 42, no. 4, pp. 305–315, May 2010, doi: 10.3109/07853891003796752.
[53]
Ele Ferrannini, ‘Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes’, European Heart Journal, vol. 36, no. 34, pp. 2288–2296, 2015 [Online]. Available: http://eurheartj.oxfordjournals.org/content/36/34/2288
[54]
C. S. Fox et al., ‘Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association’, Diabetes Care, vol. 38, no. 9, pp. 1777–1803, Sep. 2015, doi: 10.2337/dci15-0012.
[55]
C. Bianchi, R. Miccoli, and S. Del Prato, ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’, Current Diabetes Reports, vol. 13, no. 3, pp. 403–410, Jun. 2013, doi: 10.1007/s11892-013-0371-2.
[56]
K. Khunti, M. Davies, A. Majeed, B. L. Thorsted, M. L. Wolden, and S. K. Paul, ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’, Diabetes Care, vol. 38, no. 2, pp. 316–322, Feb. 2015, doi: 10.2337/dc14-0920.
[57]
R. A. Hayward et al., ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 372, no. 23, pp. 2197–2206, Jun. 2015, doi: 10.1056/NEJMoa1414266.
[58]
W. T. Cefalu, J. Rosenstock, D. LeRoith, L. Blonde, and M. C. Riddle, ‘Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”’, Diabetes Care, vol. 39, no. 5, pp. 664–667, May 2016, doi: 10.2337/dc16-0405.
[59]
J. A. Black et al., ‘Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial’, British Journal of General Practice, vol. 64, no. 621, pp. e208–e216, Apr. 2014, doi: 10.3399/bjgp14X677833.
[60]
F. M. Turnbull et al., ‘Intensive glucose control and macrovascular outcomes in type 2 diabetes’, Diabetologia, vol. 52, no. 11, pp. 2288–2298, Nov. 2009, doi: 10.1007/s00125-009-1470-0.
[61]
S. Zoungas et al., ‘Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials’, The Lancet Diabetes & Endocrinology, vol. 5, no. 6, pp. 431–437, Jun. 2017, doi: 10.1016/S2213-8587(17)30104-3.
[62]
‘Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
[63]
S. A. Saha and R. R. Arora, ‘Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials’, International Journal of Cardiology, vol. 141, no. 2, pp. 157–166, May 2010, doi: 10.1016/j.ijcard.2008.11.211.
[64]
Richard W. Nesto, ‘LDL cholesterol lowering in type 2 diabetes: what is the optimum approach?’, Clinical Diabetes, vol. 26, no. 1, 2008 [Online]. Available: http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88
[65]
‘Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus’, New England Journal of Medicine, vol. 362, no. 17, pp. 1563–1574, Apr. 2010, doi: 10.1056/NEJMoa1001282.
[66]
T. Filippatos, V. Tsimihodimos, E. Pappa, and M. Elisaf, ‘Pathophysiology of diabetic dyslipidaemia’, Current Vascular Pharmacology, vol. 15, no. 999, pp. 1–1, Feb. 2017.
[67]
M. F. Piepoli et al., ‘2016 European Guidelines on cardiovascular disease prevention in clinical practice’, Atherosclerosis, vol. 252, pp. 207–274, Sep. 2016, doi: 10.1016/j.atherosclerosis.2016.05.037.
[68]
J. White et al., ‘Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes’, JAMA Cardiology, vol. 1, no. 6, Sep. 2016, doi: 10.1001/jamacardio.2016.1884.
[69]
‘Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036
[70]
‘Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011’. [Online]. Available: http://www.nice.org.uk/guidance/cg127
[71]
‘Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus’, New England Journal of Medicine, vol. 362, no. 17, pp. 1575–1585, Apr. 2010, doi: 10.1056/NEJMoa1001286.
[72]
E. Ferrannini and W. C. Cushman, ‘Diabetes and hypertension: the bad companions’, The Lancet, vol. 380, no. 9841, pp. 601–610, Aug. 2012, doi: 10.1016/S0140-6736(12)60987-8.
[73]
UK Prospective Diabetes Study Group, ‘Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38’, BMJ : British Medical Journal, vol. 317, no. 7160, 1998 [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/
[74]
P. K. Whelton, ‘Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia’, Archives of Internal Medicine, vol. 165, no. 12, Jun. 2005, doi: 10.1001/archinte.165.12.1401.
[75]
J. I. Barzilay et al., ‘Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study’, Circulation: Cardiovascular Quality and Outcomes, vol. 5, no. 2, pp. 153–162, Mar. 2012, doi: 10.1161/CIRCOUTCOMES.111.962522.
[76]
L. H. Lindholm et al., ‘Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol’, The Lancet, vol. 359, no. 9311, pp. 1004–1010, Mar. 2002, doi: 10.1016/S0140-6736(02)08090-X.
[77]
B. Dahlöf et al., ‘Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial’, The Lancet, vol. 366, no. 9489, pp. 895–906, Sep. 2005, doi: 10.1016/S0140-6736(05)67185-1.
[78]
M. A. Weber et al., ‘Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes’, Journal of the American College of Cardiology, vol. 56, no. 1, pp. 77–85, Jun. 2010, doi: 10.1016/j.jacc.2010.02.046.
[79]
W. J. Elliott and P. M. Meyer, ‘Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis’, The Lancet, vol. 369, no. 9557, pp. 201–207, Jan. 2007, doi: 10.1016/S0140-6736(07)60108-1.
[80]
‘Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus’, New England Journal of Medicine, vol. 362, no. 17, pp. 1575–1585, Apr. 2010, doi: 10.1056/NEJMoa1001286.
[81]
R. W. Schrier, R. O. Estacio, and B. Jeffers, ‘Appropriate Blood Pressure Control in NIDDM (ABCD) Trial’, Diabetologia, vol. 39, no. 12, pp. 1646–1654, Nov. 1996, doi: 10.1007/s001250050629.
[82]
S. Bangalore, S. Kumar, I. Lobach, and F. H. Messerli, ‘Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials’, Circulation, vol. 123, no. 24, pp. 2799–2810, Jun. 2011, doi: 10.1161/CIRCULATIONAHA.110.016337.
[83]
‘Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus’, Archives of Internal Medicine, vol. 165, no. 12, Jun. 2005, doi: 10.1001/archinte.165.12.1410.
[84]
‘Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey’. [Online]. Available: https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020
[85]
‘Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998
[86]
‘Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020
[87]
S. D. Solomon et al., ‘Diabetic Retinopathy: A Position Statement by the American Diabetes Association’, Diabetes Care, vol. 40, no. 3, pp. 412–418, Mar. 2017, doi: 10.2337/dc16-2641.
[88]
N. Cheung, P. Mitchell, and T. Y. Wong, ‘Diabetic retinopathy’, The Lancet, vol. 376, no. 9735, pp. 124–136, Jul. 2010, doi: 10.1016/S0140-6736(09)62124-3.
[89]
S. Adamsson Eryd, A.-M. Svensson, S. Franzén, B. Eliasson, P. M. Nilsson, and S. Gudbjörnsdottir, ‘Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up’, Diabetic Medicine, vol. 34, no. 3, pp. 411–418, Mar. 2017, doi: 10.1111/dme.13266.
[90]
G. Liew, P. Mitchell, and T. Y. Wong, ‘Systemic management of diabetic retinopathy’, BMJ, vol. 338, no. feb12 1, pp. b441–b441, Feb. 2009, doi: 10.1136/bmj.b441.
[91]
P. Romero-Aroca, R. Navarro-Gil, A. Valls-Mateu, R. Sagarra-Alamo, A. Moreno-Ribas, and N. Soler, ‘Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study’, British Journal of Ophthalmology, Mar. 2017, doi: 10.1136/bjophthalmol-2016-310063.
[92]
P. Romero-Aroca, R. Navarro-Gil, A. Valls-Mateu, R. Sagarra-Alamo, A. Moreno-Ribas, and N. Soler, ‘Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study’, British Journal of Ophthalmology, Mar. 2017, doi: 10.1136/bjophthalmol-2016-310063.
[93]
P. Romero-Aroca, R. Navarro-Gil, A. Valls-Mateu, R. Sagarra-Alamo, A. Moreno-Ribas, and N. Soler, ‘Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study’, British Journal of Ophthalmology, Mar. 2017, doi: 10.1136/bjophthalmol-2016-310063.
[94]
S. D. Solomon et al., ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’, Diabetes Care, Apr. 2017, doi: 10.2337/dc17-er06e.
[95]
S. D. Solomon et al., ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’, Diabetes Care, Apr. 2017, doi: 10.2337/dc17-er06e.
[96]
J. B. Rosenberg and I. Tsui, ‘Screening for Diabetic Retinopathy’, New England Journal of Medicine, vol. 376, no. 16, pp. 1587–1588, Apr. 2017, doi: 10.1056/NEJMe1701820.
[97]
‘Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes’, New England Journal of Medicine, vol. 376, no. 16, pp. 1507–1516, Apr. 2017, doi: 10.1056/NEJMoa1612836.
[98]
R. B. R. Moreton, I. M. Stratton, S. J. Chave, H. Lipinski, and P. H. Scanlon, ‘Factors determining uptake of diabetic retinopathy screening in Oxfordshire’, Diabetic Medicine, vol. 34, no. 7, pp. 993–999, Jul. 2017, doi: 10.1111/dme.13350.
[99]
Melanie Davies, ‘The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies’, Clinical Pharmacology : Advances and Applications, vol. 8, 2016, doi: doi: 10.2147/CPAA.S82008. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922775/
[100]
S. D. Navaneethan, J. D. Schold, S. E. Jolly, S. Arrigain, W. C. Winkelmayer, and J. V. Nally, ‘Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD’, American Journal of Kidney Diseases, Feb. 2017, doi: 10.1053/j.ajkd.2016.11.018.
[101]
‘Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey’ [Online]. Available: https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022
[102]
D. R. Webb et al., ‘Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes’, Diabetes/Metabolism Research and Reviews, 2016, doi: 10.1002/dmrr.2877.
[103]
N. Çakici, T. M. Fakkel, J. W. van Neck, A. P. Verhagen, and J. H. Coert, ‘Systematic review of treatments for diabetic peripheral neuropathy’, Diabetic Medicine, vol. 33, no. 11, pp. 1466–1476, Nov. 2016, doi: 10.1111/dme.13083.
[104]
D. N. Koye, J. E. Shaw, C. M. Reid, R. C. Atkins, A. T. Reutens, and D. J. Magliano, ‘Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies’, Diabetic Medicine, Feb. 2017, doi: 10.1111/dme.13324.
[105]
S. Johal et al., ‘Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study’, Diabetic Medicine, Jun. 2017, doi: 10.1111/dme.13383.
[106]
M. Clokie et al., ‘New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium’, Diabetic Medicine, vol. 34, no. 3, pp. 305–315, Mar. 2017, doi: 10.1111/dme.13313.
[107]
F. Game, ‘Classification of diabetic foot ulcers’, Diabetes/Metabolism Research and Reviews, vol. 32, pp. 186–194, Jan. 2016, doi: 10.1002/dmrr.2746.
[108]
S. Jhamb, V. N. Vangaveti, and U. H. Malabu, ‘Genetic and molecular basis of diabetic foot ulcers: Clinical review’, Journal of Tissue Viability, vol. 25, no. 4, pp. 229–236, Nov. 2016, doi: 10.1016/j.jtv.2016.06.005.
[109]
A. J. Boulton, W. J. Jeffcoate, T. L. Jones, and J. S. Ulbrecht, ‘International collaborative research on Charcot’s disease - 2009’, The Lancet, vol. 373, no. 9658, pp. 105–106, Jan. 2009, doi: 10.1016/S0140-6736(09)60019-2.
[110]
M. Yavuz et al., ‘Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration’, Diabetes Care, vol. 40, no. 2, pp. e14–e15, Feb. 2017, doi: 10.2337/dc16-2204.
[111]
P Naidoo, ‘Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team’, The British Journal of Radiology, vol. 88, no. 1053, 2015, doi: doi: 10.1259/bjr.20150135. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743571/
[112]
‘Diabetic foot problems: prevention and management | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/ng19
[113]
R. I. G. Holt, ‘Understanding of the causes and management of diabetic foot disease’, Diabetic Medicine, vol. 34, no. 3, pp. 303–304, Mar. 2017, doi: 10.1111/dme.13319.
[114]
D. Jin, Y. Xu, D. Geng, and T. Yan, ‘Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials’, Diabetes Research and Clinical Practice, vol. 89, no. 1, pp. 10–15, Jul. 2010, doi: 10.1016/j.diabres.2010.03.021.
[115]
N. Çakici, T. M. Fakkel, J. W. van Neck, A. P. Verhagen, and J. H. Coert, ‘Systematic review of treatments for diabetic peripheral neuropathy’, Diabetic Medicine, vol. 33, no. 11, pp. 1466–1476, Nov. 2016, doi: 10.1111/dme.13083.
[116]
C. Foresta, A. Ferlin, A. Lenzi, and P. Montorsi, ‘The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention’, Andrology, Mar. 2017, doi: 10.1111/andr.12342.
[117]
S. Azmi et al., ‘Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study’, Diabetologia, Mar. 2017, doi: 10.1007/s00125-017-4245-z.
[118]
D. P. Andersson, Y. Trolle Lagerros, A. Grotta, R. Bellocco, M. Lehtihet, and M. J. Holzmann, ‘Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction’, Heart, Mar. 2017, doi: 10.1136/heartjnl-2016-310746.
[119]
T. Omland, A. Randby, H. Hrubos-Strøm, H. Røsjø, and G. Einvik, ‘Relation of Erectile Dysfunction to Subclinical Myocardial Injury’, The American Journal of Cardiology, vol. 118, no. 12, pp. 1821–1825, Dec. 2016, doi: 10.1016/j.amjcard.2016.08.070.
[120]
B. H. Braffett, H. Wessells, and A. V. Sarma, ‘Urogenital Autonomic Dysfunction in Diabetes’, Current Diabetes Reports, vol. 16, no. 12, Dec. 2016, doi: 10.1007/s11892-016-0824-5.
[121]
J. M. Hotaling et al., ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’, Diabetes Care, vol. 39, no. 9, pp. 1587–1593, Sep. 2016, doi: 10.2337/dc16-0059.
[122]
Giovanni Corona, ‘Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors’, PLoS ONE, vol. 11, no. 10, 2016, doi: doi: 10.1371/journal.pone.0157915. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051725/
[123]
D. Santi et al., ‘Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial’, European Journal of Endocrinology, vol. 174, no. 4, pp. 513–522, Apr. 2016, doi: 10.1530/EJE-15-1100.
[124]
‘Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321
[125]
‘Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321
[126]
L. S. Malavige, P. Wijesekara, P. Ranasinghe, and J. C. Levy, ‘The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study’, European Journal of Medical Research, vol. 20, no. 1, Dec. 2015, doi: 10.1186/s40001-015-0186-5.
[127]
J. M. Hotaling et al., ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’, Diabetes Care, vol. 39, no. 9, pp. 1587–1593, Sep. 2016, doi: 10.2337/dc16-0059.
[128]
K. K. Dhatariya and P. Vellanki, ‘Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA)’, Current Diabetes Reports, vol. 17, no. 5, May 2017, doi: 10.1007/s11892-017-0857-4.
[129]
‘Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality.’, Prime [Online]. Available: https://wwww.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_
[130]
K. Dhatariya et al., ‘NHS Diabetes guideline for the perioperative management of the adult patient with diabetes’, Diabetic Medicine, vol. 29, no. 4, pp. 420–433, Apr. 2012, doi: 10.1111/j.1464-5491.2012.03582.x.
[131]
‘The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728
[132]
A. R. Scott, ‘Management of hyperosmolar hyperglycaemic state in adults with diabetes’, Diabetic Medicine, vol. 32, no. 6, pp. 714–724, Jun. 2015, doi: 10.1111/dme.12757.
[133]
Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, , ‘Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges’, Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges [Online]. Available: http://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792
[134]
Chloe L. Edridge, ‘Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies’, PLoS ONE, vol. 10, no. 6, 2015, doi: doi: 10.1371/journal.pone.0126427. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465495/
[135]
K. Khunti, M. Davies, A. Majeed, B. L. Thorsted, M. L. Wolden, and S. K. Paul, ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’, Diabetes Care, vol. 38, no. 2, pp. 316–322, Feb. 2015, doi: 10.2337/dc14-0920.
[136]
‘Minimizing Hypoglycemia in Diabetes: Table 1’, Diabetes Care, vol. 38, no. 8, pp. 1583–1591, Aug. 2015, doi: 10.2337/dc15-0279.
[137]
F. Zaccardi et al., ‘Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation’, Diabetologia, Mar. 2017, doi: 10.1007/s00125-017-4235-1.
[138]
F. Zaccardi et al., ‘Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England’, Diabetes, Obesity and Metabolism, Apr. 2017, doi: 10.1111/dom.12941.
[139]
G. Umpierrez and M. Korytkowski, ‘Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia’, Nature Reviews Endocrinology, vol. 12, no. 4, pp. 222–232, Feb. 2016, doi: 10.1038/nrendo.2016.15.
[140]
G. Umpierrez and M. Korytkowski, ‘Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia’, Nature Reviews Endocrinology, vol. 12, no. 4, pp. 222–232, Feb. 2016, doi: 10.1038/nrendo.2016.15.
[141]
R. Micha, J. L. Peñalvo, F. Cudhea, F. Imamura, C. D. Rehm, and D. Mozaffarian, ‘Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States’, JAMA, vol. 317, no. 9, Mar. 2017, doi: 10.1001/jama.2017.0947.
[142]
K. Khunti, M. L. Wolden, B. L. Thorsted, M. Andersen, and M. J. Davies, ‘Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people’, Diabetes Care, vol. 36, no. 11, pp. 3411–3417, Nov. 2013, doi: 10.2337/dc13-0331.
[143]
S. K. Paul, K. Klein, B. L. Thorsted, M. L. Wolden, and K. Khunti, ‘Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes’, Cardiovascular Diabetology, vol. 14, no. 1, Dec. 2015, doi: 10.1186/s12933-015-0260-x.
[144]
A. Nicolucci and E. Standl, ‘Antiplatelet Therapy for Every Diabetic Person?’, Diabetes Care, vol. 34, no. Supplement_2, pp. S150–S154, May 2011, doi: 10.2337/dc11-s210.
[145]
S. Seidu, F. A. Achana, L. J. Gray, M. J. Davies, and K. Khunti, ‘Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials’, Diabetic Medicine, vol. 33, no. 3, pp. 280–289, Mar. 2016, doi: 10.1111/dme.12885.
[146]
‘The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check’. [Online]. Available: http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/
[147]
S. K. Kunutsor, S. Seidu, and K. Khunti, ‘Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials’, Diabetic Medicine, vol. 34, no. 3, pp. 316–327, Mar. 2017, doi: 10.1111/dme.13133.
[148]
L. Fisher, J. S. Gonzalez, and W. H. Polonsky, ‘The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision’, Diabetic Medicine, vol. 31, no. 7, pp. 764–772, Jul. 2014, doi: 10.1111/dme.12428.
[149]
Dana Dabelea, ‘Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood’, JAMA, vol. 317, no. 8, pp. 825–835, doi: 10.1001/jama.2017.0686. [Online]. Available: http://jamanetwork.com/journals/jama/fullarticle/2606400
[150]
‘Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626
[151]
F. Dwamena et al., ‘Interventions for providers to promote a patient-centred approach in clinical consultations’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD003267.pub2
[152]
‘Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862
[153]
P. Denig, J. Schuling, F. Haaijer-Ruskamp, and J. Voorham, ‘Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial’, BMJ, vol. 349, no. sep25 6, pp. g5651–g5651, Sep. 2014, doi: 10.1136/bmj.g5651.
[154]
M. Abdul-Ghani, R. A. DeFronzo, S. Del Prato, R. Chilton, R. Singh, and R. E. J. Ryder, ‘Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?’, Diabetes Care, vol. 40, no. 7, pp. 813–820, Jul. 2017, doi: 10.2337/dc16-2736.
[155]
S. Kaul, ‘Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials’, Diabetes Care, vol. 40, no. 7, pp. 821–831, Jul. 2017, doi: 10.2337/dc17-0291.
[156]
M. D. Ritholz, T. MacNeil, and K. Weinger, ‘Difficult conversations: adults with diabetes and the discussion of microvascular complications’, Diabetic Medicine, Jul. 2017, doi: 10.1111/dme.13419.
[157]
M. D. Ritholz, T. MacNeil, and K. Weinger, ‘Difficult conversations: adults with diabetes and the discussion of microvascular complications’, Diabetic Medicine, vol. 34, no. 10, pp. 1447–1455, Oct. 2017, doi: 10.1111/dme.13419.
[158]
R. I. G. Holt, C. S. Cockram, A. Flyvbjerg, and B. J. Goldstein, Eds., Textbook of diabetes, Fifth edition. Chichester, West Sussex, UK: Wiley Blackwell, 2017 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056
[159]
‘Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey’. [Online]. Available: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
